The induction of targets, such as GCL, requires the activation of upstream transcriptional co-activators
Therefore, Novo Nordisk does not conclude a causal relationship between GLP-1 RA use, semaglutide and age-related macular degeneration at this time. Dr Alison Cave, the chief safety officer of the Medicines & Healthcare products Regulatory Agency, a UK watchdog, said: Macular degeneration is not currently listed as a potential side-effect of these medicines
Badenhorst 2016 measured wrinkle volume reductions up to 55.8% and depth reductions of 32.8% over 12 weeks of topical use
It is not blocking a pathway, it is speeding up a repair that would otherwise take much longer or stall entirely
These findings may, in part, explain the mechanisms by which this drug exerts its positive effect on OA pathophysiology